Talent Pool

Contributed by:

NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.

Pharma POOL Richard W. Ashley James White Abbott Laboratories Names New Executives Abbott Laboratories has named Richard W. Ashley to the new position of executive VP of corporate development. Abbott, Abbott Park, Ill., is a global, broad-based healthcare company devoted to the discovery, development, manufacture, and marketing of pharmaceuticals, nutritionals, and medical products, including devices and diagnostics. Mr. Ashley was a senior director at McKinsey and Co., the managing partner of the firm’s Chicago office, and head of the firm’s global leadership and organization practice. Mr. Ashley holds a bachelor’s degree and a master’s degree in business administration from Northwestern University. He also holds a J.D. from the University of Wisconsin Law School. Abbott also has announced the expansion of its Washington, D.C., staff by naming James White to director, federal government affairs. Mr. White formerly was the legislative director for House Energy and Commerce Committee Chairman Billy Tauzin (R-LA). Mr. White earned his bachelor’s degree from the American University in Washington, D.C., where he majored in both political science and public communication. Brian A. Markison Harsha Murthy King Creates Position, Names Business Development Head King Pharmaceuticals has appointed Brian A. Markison to the newly created position of chief operating officer. Mr. Markison, President Kyle P. Macione, and chief financial officer James R. Lattanzi comprise the executive management team. King, Bristol, Tenn., is a vertically integrated branded pharmaceutical company. Mr. Markison most recently served as president of Bristol-Myers Squibb’s oncology, virology, and oncology therapeutics network businesses. He also led the successful integration of Bristol-Myers Squibb’s $7.8 billion acquisition of DuPont Pharmaceuticals in 2001. King also has named Harsha Murthy as corporate head and executive VP, strategic planning and business development. Before joining King, Mr. Murthy served as VP of administration and business strategy and general counsel at Eyetech Pharmaceuticals. He graduated from Duke University summa cum laude in 1981, where he was a member of Phi Beta Kappa, and from Stanford Law School in 1984, where he was associate managing editor of the Stanford Law Review. Michael Mawby Novo Nordisk Appoints Chief Government Affairs Officer Novo Nordisk has appointed Michael Mawby to the new position of chief government affairs officer. Novo Nordisk, with U.S. headquarters in Princeton, N.J., is a focused healthcare company with a broad diabetes product portfolio. At Novo Nordisk, Mr. Mawby influences public policy to improve the treatment, care, and healthcare coverage for people with diabetes. He is in the company’s newly opened office in Washington, D.C. Before joining Novo Nordisk, Mr. Mawby worked for the American Diabetes Association (ADA) for 10 years. At ADA, he was responsible for all of the organization’s government affairs, while managing a staff of 22 professionals working on federal, state, grassroots, and legal advocacy issues. He received a bachelor’s degree in political science, with an emphasis in international relations, from the University of Michigan. Dr. Gary L. Stiles Wyeth Names Executive VP, Chief Medical Officer Wyeth, Madison, N.J., has appointed Gary L. Stiles, M.D., as executive VP and chief medical officer for Wyeth Pharmaceuticals. Dr. Stiles joins Wyeth, one of the world’s largest research-driven pharmaceutical and healthcare products companies, from the Duke University Health System where he had been VP and chief medical officer since 1999. As chief medical officer, Dr. Stiles is responsible for the clinical research and development organization, which manages all clinical-trial studies, and global medical affairs, which supports the marketed products through further clinical development, medical education, and physician communications. After attending medical school at Vanderbilt University School of Medicine and completing his residency in cardiology at Vanderbilt Hospital, Dr. Stiles moved to Duke University as a cardiology fellow. He joined the faculty in 1981 where he assumed progressive leadership roles in Duke’s department of medicine, serving as chief of cardiology, director of the cardiology training program, and vice chair of the department of medicine. Dr. Stiles has authored more than 150 articles in peer-reviewed scientific journals and other medical publications. Biotech POOL Dr. Hal Barron Varun Nanda Dr. Patrick Yang Genentech Announces Senior Appointments Genentech, a biotechnology company based in South San Francisco, Calif., has announced three senior appointments. Hal Barron, M.D., has been promoted to senior VP of development. He joined Genentech in 1996 as a clinical scientist and most recently served as VP, medical affairs. He leads the newly formed development organization that is being created by combining Genentech’s medical affairs and development-sciences departments. Dr. Barron received his medical degree from Yale University and holds a bachelor of science degree from Washington University. Varun Nanda has been promoted to VP of sales and marketing, Avastin. Mr. Nanda joined Genentech in 1997 as director of endocrinology and most recently was senior director of sales and marketing for the solid tumor oncology franchise. Mr. Nanda holds a bachelor of engineering degree from Delhi College of Engineering and a master of business administration from Eastern Illinois University. Patrick Yang, Ph.D., has been named VP, South San Francisco manufacturing and engineering. Dr. Yang comes from Merck, where he was VP, supply chain management. Dr. Yang holds a bachelor of science degree from the National Chiaotung University in Taiwan, a master of science in electrical engineering from the University of Cincinnati, and a doctorate in electrical engineering/computer science from Ohio State. Dr. Andrew R. Blight Mary Fisher Acorda Announces Executive Promotions Acorda Therapeutics, a biotechnology company developing therapies for spinal cord injury, multiple sclerosis, and related central nervous system disorders, has announced executive promotions. Andrew R. Blight, Ph.D., previously the company’s executive VP of research and development, has been promoted to chief scientific officer. Dr. Blight is responsible for setting the strategic direction for all R&D programs and technology assessments within Acorda. Acorda Therapeutics, Hawthorne, N.Y., has promoted Mary Fisher to executive VP of operations from VP of commercial operations. She retains primary responsibility for Acorda’s marketing, sales, communications, and strategic planning. Biopharmaceutical POOL Greg Deener GTx Appoints Director of Marketing and Sales GTx, Memphis, Tenn., a biopharmaceutical company dedicated to the development of products related to men’s health, has appointed Greg Deener as director of marketing and sales. In this position, Mr. Deener is responsible for the strategic design and implementation of marketing and sales strategies. Mr. Deener brings more than 20 years experience in the design and execution of sales and marketing. He joins GTx from GlaxoSmithKline, where most recently he held the position of director, Avodart marketing. Jennifer Giottonini Idun Appoints VP, Corporate Development Jennifer Giottonini has been appointed VP of corporate development at Idun Pharmaceuticals, a San Diego-based privately held biopharmaceutical company. In this position, Ms. Giottonini is responsible for managing and expanding the company’s corporate development activities, including business development, product and technology licensing, and intellectual property management. Ms. Giottonini has more than 15 years of biotechnology and medical-device experience. She joins Idun from Isis Pharmaceuticals, where she served most recently as VP of business development. She holds a bachelor’s degree in bioengineering from University of California, San Diego. Dr. Elma S. Hawkins Advanced Viral Research Appoints CEO and President Advanced Viral Research (ADVR) has appointed Elma S. Hawkins, Ph.D., MBA, as president and CEO. ADVR, based in Yonkers, N.Y., is a biopharmaceutical company dedicated to researching and developing new and effective therapies for viral and other diseases. Dr. Hawkins continues to serve as a member of ADVR’s board of directors, a position she has held since December 2003. Dr. Hawkins has more than 20 years of business, management, regulatory, and scientific experience in the pharmaceutical and biotechnology industries. She most recently served as vice chairman of Antigenics. She also has served in a number of senior positions in corporate development, strategic planning, and regulatory and clinical affairs at Genzyme and Genzyme Tissue Repair. David M. KIES Daniel S. Lynch ImClone Systems Names CEO and Director ImClone Systems, New York, which is committed to advancing oncology care by developing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers, has named David M. Kies as chairman. Mr. Kies has served as lead director of the board since April 2003. There has been no change in Mr. Kies’ responsibilities. Daniel S. Lynch has been named as CEO and a director. Since April 2003, Mr. Lynch has served as ImClone Systems’ senior VP, chief administrative officer, and acting CEO and before that, as the company’s senior VP of finance and chief financial officer. Mr. Lynch joined ImClone Systems in April 2001 as VP of finance and chief financial officer. In September 2001, Mr. Lynch was promoted to senior VP, finance, and chief financial officer, which he served as until being named senior VP, chief administrative officer and acting CEO in April 2003. Mr. Lynch earned his bachelors degree in mathematics from Wesleyan University and a masters in business administration from the Darden Graduate School of Business Administration, University of Virginia. Paul McCabe TKT Names Country Manager for Canada As part of a strategic plan to market and sell Replagal enzyme replacement therapy for the treatment of Fabry disease in Canada upon regulatory approval, Transkaryotic Therapies has named Paul McCabe as country manager. TKT, Cambridge, Mass., in January opened an office in Toronto. Mr. McCabe joins TKT from Pharmacia Canada Inc., where he held the position of director, oncology business unit and led sales and marketing activities for this business. In this newly created position, Mr. McCabe has overall responsibility for Replagal sales and marketing initiatives, including managing product development and reimbursement. Mr. McCabe received a B.Sc. (Agr.) from the University of Guelph and a MBA from the University of Western Ontario. Dr. Dov Michaeli Dr. Patrick Mooney Aphton Appoints President and CEO Aphton has appointed Patrick Mooney, M.D., as president, CEO, and director. He formerly was chief medical officer. Miami-based Aphton is a biopharmaceutical company that develops products using its targeted immunotherapy technology for neutralizing hormones that participate in gastrointestinal system and reproductive system cancer and noncancer diseases. Dov Michaeli, M.D., Ph.D., Aphton’s senior VP, global development and medical science, has been appointed chief medical officer. Philip Gevas, Aphton’s cofounder, chairman of the board of directors, and former CEO, remains as chairman. William Hasler, the company’s vice chairman of the board of directors and former co-CEO, remains as vice chairman. Dr. Nicholas F. Paoni Industry Veteran Joins Immusol Nicholas F. Paoni, Ph.D. has joined Immusol’s senior-management team as VP of therapeutics. Immusol is a privately held San Diego-based biopharmaceutical company. Dr. Paoni leads development efforts for the company’s protein therapeutic and small molecule-based drug programs. Dr. Paoni recently served as research professor in the department of chemistry and biochemistry at the University of Notre Dame where he also was associate director of the W.M. Keck Center for Transgene Research and a member of the executive committee of the Walther Cancer Research Center. Before Notre Dame, Dr. Paoni served nearly 20 years at Genentech as a scientist in the recovery process research and development department. Dr. Paoni received a bachelor of science degree in biochemistry from the University of California, Davis, and a doctorate in chemistry with an emphasis in biochemistry from the University of Notre Dame. Specialty POOL John M. Hanson Angelo C. Malahias Thomas P. Rice Andrx Names Three Top Executives Andrx, Davie, Fla., has appointed Angelo C. Malahias as president, John M. Hanson as chief financial officer, and Thomas P. Rice as CEO. Andrx develops and commercializes: bioequivalent versions of controlled-release brand-name pharmaceuticals using its proprietary drug delivery technologies; bioequivalent versions of specialty, niche, and immediate-release pharmaceutical products, including oral contraceptives; and brand-name or proprietary controlled-release formulations of existing immediate-release or controlled-release drugs. Mr. Malahias had served as the company’s chief financial officer for eight years. He is succeeded by Mr. Hanson, who joined Andrx in April 2003 as VP, finance, and previously served as chief financial officer of Mylan Laboratories and as chief financial officer of IVAX’s U.S. generic pharmaceutical operations. Mr. Rice succeeds Richard J. Lane as CEO; Mr. Lane has resigned from the board of directors. Mr. Rice joined Andrx’s board in April 2003 and is the former president and CEO of Chesapeake Biological Laboratories. Before that, he served as chief operating officer and chief financial officer of Circa Pharmaceuticals. Dr. Klaus P. Theobald CollaGenex Pharmaceuticals Appoints Senior VP and Chief Medical Officer CollaGenex Pharmaceuticals has appointed Klaus P. Theobald, M.D., as senior VP and chief medical officer. CollaGenex, Newtown, Pa., is a specialty pharmaceutical company focused on providing innovative medical therapies to the dental and dermatology markets. Dr. Theobald brings 18 years of clinical and regulatory experience at domestic and international life-sciences companies to this new position. He is responsible for developing future products emerging from CollaGenex’s proprietary drug-development efforts. Dr. Theobald assumes the research and development responsibilities previously held by Robert A. Ashley, who left his position as senior VP, commercial development of CollaGenex to become chairman, president, and CEO of Amplimed. Mr. Ashley has agreed to serve as a consultant to CollaGenex through the end of the year. Dr. Theobald joins CollaGenex from Allergenics, an early-stage biotechnology company focused on oral protein delivery, where he was president and CEO. He previously spent 16 years at Aventis Behring, most recently serving as chief medical officer of Aventis Behring’s genesis therapeutics subsidiary. Dr. Theobald received his doctorate in medicine from the Johannes Gutenberg University in Mainz, Germany, where he focused on medical microbiology and immunology. Dr. Stephen L. Warren Atrix Names Chief Scientific Officer Atrix Laboratories has added chief scientific officer to the duties of Stephen L. Warren, M.D., VP of research and development. Atrix Laboratories, Fort Collins, Colo., is an emerging specialty pharmaceutical company focused on advanced drug delivery. Dr. Warren joined Atrix in January 2002. From 1989 to 1997, Dr. Warren held faculty positions in the departments of pathology and biology at Yale University School of Medicine. He also served as an attending physician in the Department of Pathology, Yale-New Haven Hospital. During his tenure as an academic physician, he acted as a consultant to medical, surgical, and radiation oncologists. Dr. Warren has extensive experience in the field of cancer research. He also is a diplomate with the American Board of Anatomic Pathology. Dr. Warren has published extensively on mechanisms of cellular growth regulation. Among his positions within the biotechnology industry, Dr. Warren has served in leadership positions at such companies as NeXstar Pharmaceuticals, Gilead Sciences, and Allos Therapeutics. Drug/Delivery POOL Dr. Lynn Gold Dr. Neile Grayson Dean Kessler Sonus Pharmaceuticals Expands Drug-Development Organization Sonus Pharmaceuticals has appointed Lynn Gold, Ph.D., as VP of research and process development, Neile Grayson, Ph.D., as VP of strategic planning and corporate development, and Dean Kessler as VP of preclinical development. Sonus, Bothell, Wash., applies expertise in drug delivery to design and develop novel dosage forms that improve the administration, tolerability, and effectiveness of therapeutic pharmaceuticals. In her new position, Dr. Gold oversees discovery research, formulation development, analytical chemistry, manufacturing, and quality control at Sonus. Her previous experience includes 13 years at Fresenius Kabi where she had responsibility for product development as well as business development activities. Dr. Grayson joins Sonus from NeoRx where she served as VP of corporate development. Her past experience also includes nine years at Mallinckrodt, where she directed activities related to identifying and assessing corporate growth opportunities. In her new role at Sonus, Dr. Grayson provides strategic insights to the selection of research and development projects and identifies and markets the company’s technology and products to prospective commercial partners. Mr. Kessler has more than 16 years of experience in the preclinical evaluation of new pharmaceuticals. He joined Sonus in 1992 as a research scientist. As VP of preclinical development, Mr. Kessler has responsibility for all aspects of biological screens, experimental nonclinical pharmacology, and nonclinical safety assessments for new products. Dr. Su IL Yum Durect Announces Promotion and Management Change Durect, which is developing and commercializing pharmaceutical systems for the treatment of chronic debilitating diseases and enabling biotechnology-based pharmaceutical products, has promoted Dr. Su Il Yum to senior VP of engineering. Before joining Durect, Cupertino, Calif., Dr. Yum served as senior technical advisor at Amira Medical, where he participated in the development of a pain-free glucose detector called AtLast. Before joining Amira, he held a number of senior positions in project management and engineering at Alza. Dr. Yum earned his Ph.D. degree in chemical engineering from the University of Minnesota, and completed postdoctoral research in biomedical engineering at the University of Utah. He has authored more than 40 scientific publications and is the inventor of more than 60 U.S. and foreign patents. Russell M. Savre Nobex Personnel Changes Support Drug Pipeline Advancements Nobex, a drug-development company specializing in drug delivery based in Research Triangle Park, N.C., has appointed Russell M. Savre as VP of finance and administration. Mr. Savre replaces the former chief financial officer, Chuck Osborne, who resigned to become the chief financial officer of Scynexis. Mr. Savre is responsible for financial, administrative, facilities, and IT functions at Nobex. Mr. Savre recently was senior VP and chief financial officer of A.M. Pappas & Associates and brings 30 years of operational, managerial, and financial experience. Device/Diagnostic POOL Dr. Vartan Ghazarossian FlowMedica Names President and CEO FlowMedica, a medical-device company developing intravascular systems for facilitating the management of life-threatening renal conditions, has appointed Vartan Ghazarossian, Ph.D., as president and CEO. Dr. Ghazarossian joins FlowMedica, Fremont, Calif., from cardiovascular device company DyeRx Medical, where he was president and CEO. Previously, he served in a similar position at Imetrx. Since 1998, he also has been an executive partner of Nortech Venture, a medical-technology germinator. Dr. Richard D. Gill Signet Laboratories Appoints President and CEO Dr. Richard D. Gill has joined Signet Laboratories as president and CEO succeeding founder Dr. Ronald J. Casciato, who has assumed the role of executive chairman. Signet, Dedham, Mass., is a privately held medical diagnostics/research company. Dr. Gill has more than 25 years of strategic management, research, and technology commercialization experience in the life-sciences industry. Dr. Gill most recently was the president and CEO of AnVil. Dr. Gill holds a Ph.D. in endocrinology and a B.Sc., with honors in physiology and biochemistry, from Reading University, United Kingdom. Dr. Timothy J. Pelura Dr. Dennis P. Riley Kereos Appoints Chief Technology Officer and VP, Development Kereos, a company developing targeted therapeutics and molecular imaging agents for detection and treatment of cancer and cardiovascular disease, has appointed Timothy J. Pelura, Ph.D., to the position of chief technology officer, and Dennis P. Riley, Ph.D., to the position of VP of development. As chief technology officer, Dr. Pelura is responsible for the development of St. Louis-based Kereos’ product pipeline. Dr. Pelura has a proven track record in all phases of medical product development that spans more than 28 years. Before Kereos, he was president and chief operating officer at Provasis Therapeutics. He has held positions such as VP of research and development for Neuron Therapeutics and Alliance Pharmaceutical, in addition to holding various positions at Pharmacia. Dr. Pelura holds a Ph.D. in chemistry from Rutgers University. Dr. Riley oversees preclinical development as well as process and analytical chemistry in his role as VP of development. Previously, he was senior VP of research and development at MetaPhore Pharmaceuticals, where he successfully led all of MetaPhore’s research and development efforts. Dr. Riley joined MetaPhore in 1999 as VP of research, following a 15 year career at Monsanto. Dr. Riley holds a Ph.D. in inorganic chemistry from Ohio State University. Genomics POOL John Boyce Rick Episcopo Dr. Kevin Krenitsky Genomics Collaborative Announces Appointments Genomics Collaborative (GCI) has appointed John Boyce as senior director of business development, Rick Episcopo as president, and Dr. Kevin Krenitsky as senior VP of business development. GCI, Cambridge, Mass., is pioneering the application of human genetics to target validation for drug discovery and diagnostics. Mr. Boyce most recently served as director, U.S. sales, at Sequenom, where he led the successful expansion of Sequenom’s MassARRAY system and consumable business in the United States. Mr. Episcopo served as executive VP of commercial operations at Sequenom from July 2000 through June 2003, where he oversaw global sales, marketing, and customer support for the company’s genetic systems business. Mr. Episcopo is a graduate of the United States Naval Academy. Dr. Krenitsky, who had been senior VP and medical director, now leads new business efforts full time. Elizabeth Hutt Dr. Anne Kopf-Sill Dr. John Todd NuGEN Expands Management Team NuGEN Technologies, San Carlos, Calif., a privately held company developing and commercializing products for high sensitivity nucleic acid amplification and detection, has appointed three new members to its executive management team: Elizabeth Hutt, M.S., as VP of sales and service, Anne Kopf-Sill, Ph.D., as VP of product development, and John Todd, Ph.D., as VP of marketing. Ms. Hutt has almost 15 years of leadership experience in diversified sales and marketing. Before joining NuGEN, she was VP of sales and service, North America and Pacific Rim, at Tripos. Ms. Hutt received her M.S. in business administration from Central Michigan University and B.A. in chemistry from Michigan State University. As VP of product development, Dr. Kopf-Sill oversees the development of NuGEN’s expanding product line based on the company’s proprietary SPIA and Ribo-SPIA technologies. Dr. Kopf-Sill brings more than 15 years of experience in developing increasingly complex research and diagnostic products. Before joining NuGEN, she was VP of new products at Caliper Technologies. She is an inventor with more than 30 microfluidics and diagnostic patents, and has a Ph.D. in chemical engineering from Stanford University. Dr. Todd brings to NuGEN 20 years of diversified experience in marketing, technology, product strategy development, licensing, and fundraising. Dr. Todd provides commercial direction for the Ovation product line, market expansion of the company’s research products portfolio, and diagnostic applications of NuGEN’s proprietary technologies. Most recently, he was an independent business consultant advising biotechnology clients Dr. Todd has a Ph.D. in biochemistry from the University of Southern California Medical Center. CRO POOL Dr. Martha R. Feller Kendle Names Pharma Industry Veteran to Lead North American and Latin American Operations Kendle International, a full-service contract research organization, has named Martha R. Feller, Ph.D., as senior VP of the company’s Americas Operating Unit (OU). Dr. Feller serves on Kendle’s executive committee and is based in Kendle’s Cincinnati headquarters. Dr. Feller provides executive leadership for Kendle’s Phase I-III clinical development service offerings in North America and Latin America and is overseeing the company’s expansion into Central America and South America. She joins Kendle from Procter & Gamble Pharmaceuticals, where she most recently was associate director, new drug development, responsible for leading the company’s global development and regulatory approval efforts for a new female testosterone patch therapy. Dr. Feller’s expertise spans all phases of drug development for both prescription and over-the-counter products in a range of therapeutic areas, with a strong focus on androgen and other female hormone therapies. Dr. Feller earned a doctorate in biochemistry from the University of Cincinnati College of Medicine and a bachelor of science in chemistry and mathematics from Edgecliff College. Gisela Leon AAC Consulting Group Adds Senior Consultant to Staff AAC Consulting Group, a subsidiary of Cincinnati-based Kendle International, has appointed Gisela Leon as senior consultant. In her new role, Ms. Leon provides label reviews and consulting assistance for foreign labeling requirements. She brings to AAC 25 years of European food labeling experience and an expertise in European food law and legal clearance of package labeling and multilanguage labeling. She most recently served as director, quality management, with Schoeller Lebensmittel GmbH & Co KG, Germany. She received her master of business administration from George Mason University in Virginia and a master of science in food technology engineering from Technical University of Munich. Service POOL Guy M. Amato Katherine Dietzen Access Worldwide Undergoes Management Changes Access Worldwide Communications, a marketing services organization based in Boca Raton, Fla., has announced changes to the management of the company’s TMS Professional Markets Group, a pharmaceutical marketing company that provides product detailing, clinical-trial recruitment, and educational services. Guy M. Amato has been named president and CEO of TMS. Mr. Amato joined Access Worldwide in March 2002 as senior VP, sales and marketing, and was promoted to executive VP in July 2003. He has more than 17 years of pharmaceutical and marketing experience. Previously, he was a sales director at Wellpoint Pharmacy Management. As part of the six-month transition plan, Lee Edelstein resigned as president and CEO of TMS. Mr. Edelstein continues to provide consulting services to the company and works with Shawkat Raslan, chairman and CEO of Access Worldwide, on business and new program development for all pharmaceutical marketing services. Mr. Edelstein founded TMS in 1992. He relinquished his role as president in 2000 and returned at the request of the board in March 2002. He had been a member of the board since October 1997 and a consultant to Access Worldwide since June 1999. In conjunction with these changes, the company created Access Pharmaceutical Services, a joint effort between TMS and the company’s AM Medica Communications Group, that markets Access Worldwide’s pharmaceutical capabilities, responds to sales leads, develops customized programs across both companies when appropriate, and executes these programs on behalf of pharmaceutical clients. As part of the creation of Access Pharmaceutical Services, Katherine Dietzen, senior VP of Access Worldwide and chief operating officer of AM Medica, reports directly to Mr. Amato. Dr. James R. Bosley Jr. Cynthia Stephens Pharsight Appoints Senior Director of Product Management and Senior VP, CFO Pharsight, a provider of science and information technology-based software and consulting services to accelerate clinical-drug development, has named James R. Bosley Jr., Ph.D., as senior director of product management, and Cynthia Stephens as senior VP and chief financial officer. Dr. Bosley brings extensive modeling and simulation, information technology, and marketing experience to Pharsight, Mountain View, Calif., with a strong background in the pharmaceutical and biotechnology industries. In this position, Dr. Bosley is responsible for setting the priorities to extend Pharsight’s current software product portfolio. Before joining Pharsight, Dr. Bosley served as consulting director for Rosa Pharmaceuticals. Before Rosa, Dr. Bosley spent more than three years as a systems engineer at Entelos. Dr. Bosley received his B.S. from the University of Wisconsin and his Ph.D. from the University of Texas at Austin. He also earned a M.S. in electrical engineering from University of California-Irvine. Ms. Stephens, who originally joined Pharsight in October 2003 as the company’s interim chief financial officer, brings more than 15 years of financial management experience in the high-tech industry to Pharsight. Before joining Pharsight, Ms. Stephens served as VP of finance at Rainmaker Systems. Before Rainmaker, she was interim VP of finance at Calico Commerce Corey Eagan Analyst Added to MBS/Vox Staff MBS/Vox, CommonHealth’s research-based consultancy unit located in Wayne, N.J., that specializes in physician-patient communication, has added Corey Eagan to the staff as an analyst. CommonHealth is a leading healthcare-communications resource and a WPP Group company. In this position, Ms. Eagen uses her linguistic background to aid in the examination of interpersonal communication within a doctor’s office to help clients better understand the physician-patient relationship. Before this, Ms. Eagan was employed as a client service administrator with Comprehensive Health Services. She holds a bachelor’s degree in linguistics from Georgetown University. Steve Feld Alyona Romanchuk Dae Son DoctorNet Announces Appointments and Promotion The DoctorNet, a New York-based company that specializes in interactive e-mail marketing to physicians, has promoted Steve Feld to director of sales and marketing. He is responsible for establishing new relationships with pharmaceutical companies and medical-device manufacturers who want to broadcast e-mail messages to their doctor customers. Alyona Romanchuk has been appointed as director of database management. She maintains and works to grow the 200,000 e-mail address database for doctors in 55 specialties. Dae Son has been appointed IT director. He is in charge of operations and quality control of the several hundred thousand weekly e-mail broadcasts from DoctorNet servers. James W. FitzGibbons Barbara Lyster David Shenk NDCHealth Announces Management Changes NDCHealth has appointed James W. FitzGibbons as VP, finance, and Barbara Lyster as executive VP, pharmaceutical services operation. NDCHealth, Atlanta, is a provider of health information solutions. In this role, Mr. FitzGibbons is responsible for broad support of NDCHealth’s corporate-wide financial administration and serves as the chief accounting officer for the company. Before joining NDCHealth, he was VP, controller for McKesson’s information solutions business. Mr. FitzGibbons received his bachelor of science degree in accounting from the University of Alabama. In her role, Ms. Lyster is responsible for overseeing strategic direction and day-to-day operational performance of her busin ness unit, including data integrity, client services, and trade relations. She is located at the company’s Phoenix data-center operations. Before joining NDCHealth, she was with Dendrite International, where she served for a year and a half as VP of European operations. Before that, she spent 18 years at Glaxo Wellcome as VP of U.S. information systems. David Shenk, formerly controller and chief accounting officer, has assumed a new role as senior VP, planning and analysis, reporting to the chief financial officer. George L. Fotiades Ronald K. Labrum James F. Millar Mark W. Parrish Cardinal Health Announces Organizational Changes Cardinal Health, Dublin, Ohio, a provider of products and services supporting the healthcare industry is creating greater customer focus and enhancing the company’s opportunities for growth with several management changes. All company operations now report to George L. Fotiades, who has been promoted to the newly created position of president and chief operating officer. Mr. Fotiades has been president and CEO of Cardinal Health’s life-sciences business since 2000 and continues to lead this business on an interim basis until his replacement is named. Mr. Fotiades joined Cardinal Health in 1998 from R.P. Scherer Corp., where he was group president. Mr. Fotiades also serves as a director of Prologis. In addition, the company also appointed James F. Millar to the newly created position of executive director, strategic initiatives. Mr. Millar advises chairman and CEO Robert D. Walter and Mr. Fotiades on strategy related to pharmaceutical distribution and healthcare provider opportunities. He also represents the company’s interests on important industry issues. Previously, Mr. Millar was president and CEO of healthcare products and services. Ronald K. Labrum has been promoted to president and CEO of the newly created Integrated Provider Solutions organization. Mr. Labrum previously was executive VP and group president of medical products and devices. Mark W. Parrish, executive VP and group president of the pharmaceutical distribution business, has added pharmacy franchise operations to his current responsibilities. Mr. Parrish has held a number of senior-level pharmaceutical distribution roles since joining the company in 1993. He was president of Medicine Shoppe International from 2001 until his appointment to group president in early 2003. Peter C. Kershaw Millipore Appoints VP, Worldwide Manufacturing Operations Peter C. Kershaw has joined Millipore as VP of worldwide manufacturing operations and is a member of Millipore’s top management team. Millipore, Billerica, Mass., is a multinational bioscience company that provides technologies, tools, and services for the discovery, development, and production of new therapeutic drugs. In this role, Mr. Kershaw leads Millipore’s worldwide manufacturing strategy and operations. Mr. Kershaw also has responsibility for Millipore’s supply chain, health, safety and environment, manufacturing engineering, and corporate facilities groups. Mr. Kershaw joins Millipore from Hologic, where he was corporate VP of manufacturing operations. Mr. Kershaw holds a MBA from Duquesne University, a B.S. degree in industrial engineering from Lehigh University, and a B.A. in pre-engineering from Elizabethtown College. Sheila Hale Ogle Tom Sturgis Integrated Clinical Trial Services Names CEO and President Integrated Clinical Trial Services (ICTS) has named Sheila Hale Ogle as CEO. She oversees all management and strategic planning. ICTS recently was formed as a more effective approach for pharmaceutical, biotech, and medical-device companies to recruit patients in clinical trials without enduring costly delays. Ms. Ogle has received a number of awards for her professional, civic, and community work, including the national Rising Star Award from the Business Women’s Network at the Diversity Women Leadership Summit, the Triangle Business Journal’s Women in Business Lifetime Achievement Award, and the National Association of Women Business Owners’ (NAWBO) National Woman Business Owner of the Year Award. ICTS has named Tom Sturgis as the company’s president. He oversees the day-to-day activities and financial operations of the company. Mr. Sturgis has more than 10 years of experience in patient recruitment and medical communication with well-known industry firms and 20 years of experience in management and finance. Norman Stalsberg Health Process Management Names President Norman Stalsberg has been named president of Health Process Management, Doylestown, Pa. HPM is inChord Communication’s healthcare data management and analytics firm. Mr. Stalsberg adds the title of president and expanded responsibilities to his current role as president of CHS, another inChord company. Mr. Stalsberg joined CHS in 1999 and was named president in 2002. Before joining inChord, he was VP and general manager for the Consumer Products Group at NDC Health. He holds a bachelor’s degree from Occidental College. Contract-Sales POOL Alan L. Rubino PDI Appoints Executive VP and General Manager PDI, a healthcare sales and marketing company, has named Alan L. Rubino as executive VP and general manager, sales teams business. Mr. Rubino manages PDI’s biopharmaceutical salesforce solutions business unit. Mr. Rubino most recently was senior VP of the pharmaceuticals technology and services division within Cardinal Health. He joined Cardinal Health as part of the acquisition of BLPG Inc., a healthcare marketing services company, where he was the executive VP and managing director. Before joining BLPG, Mr. Rubino held key executive positions in sales, marketing, and operations within Hoffmann-La Roche, most recently holding the position of VP of business operations. Medical-Education POOL Dr. John J. Delfino AAF-MED Names Medical Director AAF-MED, the independent ACCME-accredited subsidiary of The Curry Rockefeller Group of Companies, Tarrytown, N.Y, has name John J. Delfino, DMD, as medical director. Dr. Delfino is currently clinical professor of maxillofacial surgery and director of clinical research and development at the NYU Medical Center of Maxillofacial Surgery. Dr. Delfino has authored more than 50 publications, has lectured extensively, and has been the principle investigator in more than 30 research studies. He received a B.S. from College of the Holy Cross and a D.M.D. from Temple University School of Dental Medicine. Blanca N. Diaz Fission Communications Creates Director of Meeting Services Position Fission Communications has promoted Blanca N. Diaz, CMP, to the newly created position of director of meeting services from her role as manager, meeting services. New York-based Fission, a division of Regan Campbell Ward, focuses on cultivating and disseminating clients’ share driving and disease-based educational messages through medical education. Before joining Fission, Ms. Diaz acted in a consulting capacity with her company, BND Meeting Services. Ms. Diaz has been an active member of the Meeting Professionals International Greater New York Chapter since 1994 and is currently the president-elect for 2003-2004. She received her certified meeting professional designation in 1996. She has a bachelor’s degree in business administration from Pace University and a certificate in meeting and conference management from New York University. Tarun Mathur Medsn Promotes R&D Director to Chief Technology Officer Medsn, a medical-education company, located in Culver City, Calif., has promoted Tarun Mathur to chief technology officer. Mr. Mathur, who joined Medsn at its inception in 1999, most recently was director of research and development. Mr. Mathur’s technical expertise includes in-depth knowledge of e-learning industry technologies. In addition, he has expertise in enterprise class software development for both online and offline applications. Mr. Mathur completed his undergraduate studies in physics with a concentration in medical physics at the University of California, Irvine. Mark Rickards Cadent Medical Communications Announces Promotion Cadent Medical Communications, a medical-education and communication company, has promoted Mark Rickards to president. Cadent Medical Communications, Irving, Texas, is a subsidiary of inChord Communications. Mr. Rickards joined the organization in January 2003 as chief operating officer. Before that, Mr. Rickards served for more than 15 years in various sales and marketing roles at AstraZeneca. Mr. Rickards also has therapeutic experience in cardiovascular, urology, respiratory, anti-infectives, and pain management. He holds a bachelor’s degree in marketing and entrepreneurship from Baylor University. Dr. Martin Skelton Healthworld Names Medical-Education Division President Healthworld Communications Group has appointed Martin Skelton, Ph.D., to president of the medical-education division. Healthworld, New York, is an international communications organization specializing in healthcare. Before joining Healthworld, Dr. Skelton held several positions at Phase Five Communications, one of the medical-education divisions of Grey Healthcare Group, including director of scientific services, director of Phase Five Publications, and senior VP, associate director of Phase Five. Dr. Skelton holds a bachelor of science degree in biology (first class honors) and a doctor of philosophy degree in neurophysiology from the University of Wales, United Kingdom. Andrea Throckmorton Project Coordinator Promoted at Phoenix Marketing Solutions Phoenix Marketing Solutions, a medical-education company that specializes in tailor-made programs for pharmaceutical clients, has promoted Andrea Throckmorton to project manager, assigned to the Bristol-Myers Squibb account. She previously was a senior project coordinator at Phoenix. She is a graduate of Richard Stockton College. Media POOL Meg Ainley Rob Braun Don Bruccoleri Tina Feliciano Angie Hiller Mary Ellen Jones Advanstar Medical Economics Announces Changes for Several Publications Advanstar Medical Economics, a unit of Advanstar, a Boston-based worldwide business information company serving specialized markets with high-quality information resources and integrated marketing solutions, has announced appointments for several publications. Meg Ainley has been promoted to publisher for Drug Topics from national sales manager, a position she held for more than two years. She has been with the publication since 1995. As publisher, she is responsible for all aspects of the day-to-day business. Rob Braun has been named associate publisher for Geriatrics. Most recently, Mr. Braun worked at Medsite as director of business development for their e-detailing programs and Internet-based CME. As associate publisher, Mr. Braun is responsible for pharmaceutical page advertising and media project sales. Don Bruccoleri has been named associate publisher for Patient Care, with responsibility for media and project sales. Previously, he had been senior account manager for both Patient Care and Medical Economics. Tina Feliciano has been promoted to account manager on Contemporary OB/GYN. She has been working on all the Contemporary Group publications as a technology account manager responsible for inside sales. In her new position, she assists with pharmaceutical advertising and media project sales. Angie Hiller has been named associate publisher for JAAPA and Patient Care for the Nurse Practitioner. She joined the company in 1998 as an account manager. In 2000, she was named national sales manager. Mary Ellen Jones has been named associate publisher for Contemporary OB/GYN, having been a senior-account manager on the publication for almost a year. She is responsible for Contemporary OB/GYN’s media and project sales. Agency POOL Juliana Aristizabal Joena Liban Dave McCarty Torre Lazur Introduces New Account Team for Depakote Torre Lazur McCann Healthcare Worldwide, with headquarters in Parsippany, N.J., hired three account-service employees to work on advertising for Abbott’s Depakote, which treats conditions of the nervous system, certain forms of epilepsy, mania associated with bipolar disorder and prevention of migraine headaches; and once-daily Depakote ER, for epilepsy and migraine prevention. Juliana Aristizabal, account supervisor, joins TL Chicago from sister agency Torre Lazur Toronto. She brings more than five years of experience. Joena Liban, a recent graduate of Columbia College Chicago, also joins the team as account coordinator. The Chicago Depakote Team is led by Dave McCarty VP, management supervisor. He has more than 25 years of experience in medical education, strategic consultancy, Internet development, advocacy/public relations, and innovative media. Torre Lazur McCann Healthcare Worldwide, an international healthcare marketing communications organization, is a unit of McCann-Erickson Worldgroup, a global marketing communications organization and part of the Interpublic Group of Companies . Koonam Aurora Lisabeth Rodrigues Nelson Communications Names Account Supervisor Nelson Communications, a New York-based healthcare marketing communications company and member of the Publicis Healthcare Communications Group, has hired Koonam Aurora as an account supervisor. Previously, Ms. Aurora was an education director at IntraMed Scientific Solutions. Ms. Aurora holds a bachelor of science degree from Tufts University. Nelson Communications also hired Lisabeth Rodrigues as media coordinator. Susan Baranowski Clare Carroll D.J. Jaffe Scott Morris Doug Plessinger David Querry Scott Tannenbaum Caroline Waloski GSW Names Executive Staff Additions have been announced to the executive staff of Gerbig, Snell/Weisheimer’s, Columbus, Ohio, and New York offices. Gerbig, Snell/Weisheimer (GSW) is an independent healthcare advertising agency and a subsidiary of inChord Communications. Susan Baranowski has been named VP, account director, in Columbus. Before GSW, Ms. Baranowski served as VP, group account supervisor at Interpublic Group. She holds a bachelor’s degree from the University of California, Irvine. Clare Carroll has been named global VP, client services, New York. Before GSW, she served as VP, group account supervisor of the GlaxoSmithKline NeuroHealth Divison at Foote, Cone & Belding. She holds a master’s degree of pharmacy from Columbia University’s College of Physicians and Surgeons and a bachelor’s degree from Adelphia University. D.J. Jaffe has been named VP, creative director, in the New York office. Before GSW, Mr. Jaffe served as creative director at Margeotes, Fertitta & Partners. He holds a master’s and bachelor’s degree from New York University. Scott Morris has been named associate creative director in Columbus. Before GSW, Mr. Morris served as associate creative director at Temerlin McClain. He holds a bachelor’s degree from Purdue University. Doug Plessinger has been named VP, account director, based in Columbus. Before GSW, Mr. Plessinger worked for Millennium Pharmaceuticals and Bristol-Myers Squibb Oncology. Mr. Plessinger is a licensed pharmacist. He holds a bachelor’s degree from Northeastern University’s College of Pharmacy and Allied Health. David Querry has been named VP, account director. Before joining GSW in Columbus, Mr. Querry served as director of attention deficit hyperactivity disorder products at Shire US. He holds a bachelor’s degree from Hillsdale College. Scott Tannenbaum has been named senior VP, client services, in New York. Previously, Mr. Tannenbaum served as VP, management supervisor, at The Martin Agency. He holds a master’s and bachelor’s degree from the University of Rochester. Caroline Waloski has been named VP, associate creative director, in the New York office. Before GSW, she served as associate creative director/VP at Robert A. Becker, Euro RSCG. She holds a bachelor’s degree from The Cooper Union. Jeff Boose Patrick J. Mulvey Ross Thomson Grey Healthcare Group Adds to Executive Team Grey Healthcare Group (GHG) has named Jeff Boose as GHG chief financial officer worldwide, Patrick J. Mulvey as senior VP and director of human resources, and Ross Thomson, as chief creative officer. With headquarters in New York, GHG provides an array of integrated services and is a wholly owned partner company of Grey Global Group. Mr. Boose, formerly Grey Global Group’s director of financial, began his career at Moody’s Investors Service in 1989. Mr. Mulvey manages GHG’s worldwide human resources departments. He previously spent 18 years with Time Warner, most recently serving as VP of human resources at Bookspan. Before joining GHG, Mr. Thomson was creative copy director at Cogent Elliot, the largest independent agency in the United Kingdom, after becoming creative director/ board director at McCann-Erickson, Scotland. Sean Corcoran Frank Edwards Elizabeth Haight Jody Hayes Mirek Janczur Danielle Lewis Jeremy Lichtenberger Amanda Pelchat Michelle Petroff Lee Randolph Philip Reynolds Dr. Linda Ritter Palio Communications Announces Appointments Palio Communications, a full-sevice advertising and communications agency located in Saratoga Springs, N.Y., has announced staff appointments. Sean Corcoran has been named an account coordinator. Mr. Corcoran previously was a licensing coordinator with World Wrestling Entertainment. He holds a bachelor’s degree from Alfred University. Frank Edwards joins Palio as art director from Jay Advertising. In that position his client roster includes Warner-Chilcott, High Falls Brewing Company, The United Way of Greater Rochester, and PGA of America. He holds a bachelor of fine arts degree from the Rochester Institute of Technology. Elizabeth Haight has been named a project manager. Ms. Haight joins Palio from Kaleel Jamison Consulting Group. She holds a degree in graphic design from The Sage Colleges of Albany. Jody Hayes has been promoted to senior account executive from account executive. She joined Palio in 2002. Her primary account is GlaxoSmithKline HIV. She holds a MBA from Sage Graduate School and a B.S. from Siena College. Danielle Lewis has been promoted to assistant account executive from account coordinator. She joined Palio in 2002 and her primary account is GlaxoSmithKline HIV. Previously she was co-chair for the AIDS Awareness Coalition. She holds a B.A. from Mount Holyoke College. Jeremy Lichtenberger has been promoted to account supervisor from senior account executive. He joined Palio in 2001 and his primary account is GlaxoSmithKline HIV. Previously, he was an account executive at Foote, Cone & Belding HealthCare. He holds a B.S. from Mount Saint Mary’s College. Mirek Janczur has been named as an advertising designer. Mr. Janczur previously was a graphic artist at Media Logic. He received a bachelor’s in fine arts degree from the Pratt Institute. Amanda Pelchat has been named account coordinator from administrative assistant. She joined Palio in 2003 and her primary account is Valeant Pharmaceuticals. She holds an AAS from Sage College of Albany. Michelle Petroff has been promoted to account supervisor from account executive. She joined Palio in 2001 and her primary account is Acorda Therapeutics. Her previous experience includes serving as an electronic data interchange implementation specialist at General Electric Information Services and a marketing position at CHS. She holds a B.S. from Pennsylvania State University. Lee Randolph has been named account director. Ms. Randolph most recently served as account supervisor at Torre Lazur McCann. She holds a bachelor’s degree from The State University of New York at Buffalo. Philip Reynolds has been promoted to senior copywriter from copywriter. He joined Palio in 2000 and his primary account is GlaxoSmithKline HIV. His previous experience includes serving as principal at Philip Reynolds Editorial Services; production editor at Abbeville Press; and editorial/production associate at Roundtable Press. He holds a B.A. from Skidmore College. Linda Ritter, Ph.D, has been promoted to associate medical director from medical information specialist. She joined Palio in 2002 and her primary accounts are GlaxoSmithKline Oncology and SuperGen. Previously she was a postdoctoral fellow at the National Cancer Institute’s Laboratory of Cellular Carcinogenesis and Tumor Promotion. She holds a B.S. from Xavier University and a Ph.D. from The Ohio State University. Dr. Mitchell D. Greenberg HealthSTAR Communications Names Strategic Development/Medical Education VP HealthSTAR Communications has named Mitchell D. Greenberg, M.D., as senior VP of strategic development/medical education. HealthSTAR, Woodbridge, N.J., is a healthcare communications network. Dr. Greenberg represents the HealthSTAR network of companies to the pharmaceutical industry, including the integration of the various medical-education resources to achieve more efficient transfer of knowledge. He also serves as the acting medical director for several of the companies in the HealthSTAR network. During the last 20 years, Dr. Greenberg has been a healthcare provider specializing in women’s health, worked in hospitals in academic centers, and, most recently, was an executive for a healthcare education company. He has specific expertise in new business development and the design and production of post-graduate CME educational activities, thought-leader programs, focus groups, home-study enduring material products, speakers’ bureaus, presentation and content and curriculum development and participates in research and publication strategies for various clients. Frank Moos Trinity Communications Names Senior VP, Director of Client Services Trinity Communications, a provider of medical marketing and education programs located in Media, Pa., has hired Frank Moos as senior VP, director of client services. Most recently, Mr. Moos was president and chief operating officer of the Saatchi & Saatchi division, Creativity in Practice. He is a graduate of Temple University. He holds an undergraduate degree as well as a MBA. John B. Osborn President and CEO Appointed for BBDO New York John B. Osborn has been appointed president and CEO of BBDO New York. BBDO New York is part of BBDO Worldwide, a part of Omnicom Group Inc. Mr. Osborn, 37, most recently was executive VP and director of integrated marketing for BBDO North America. Mr. Osborn joined BBDO New York in 1991. He also has been the principal architect and engineer of the agency’s integrated communications service offering. Mark Reichman TALENT pool Noesis Healthcare Adds to Account Management Team Noesis Healthcare Interactions, a CommonHealth professional advertising and promotion agency located in Morristown, N.J., has added to its account management team. Mark Reichman has joined Noesis as a VP, account group supervisor. In this position, he spearheads the development and execution of marketing initiatives for his assigned accounts. Previously Mr. Reichman served as VP, account group supervisor, at Integrated Communications. Please send your personnel announcements to feedback@pharmavoice.com. Dr. Lester M. Crawford Dr. Mark McClellan President George W. Bush has tapped Food and Drug Administration commissioner Mark McClellan, M.D., Ph.D., to be the administrator of the Centers for Medicare and Medicaid Services at the Department of Health and Human Services. Dr. McClellan previously served as a member of the White House Council of Economic Advisers. Before that position, he worked at Stanford University as an associate professor and director of the program on health outcomes research. He also was an attending physician for internal medicine at Stanford Health Services. Dr. McClellan earned his bachelor’s degree from the University of Texas, his master’s degree from Harvard University, his medical degree from Harvard-MIT Division of Health Sciences and Technology, and his Ph.D. from Massachusetts Institute of Technology. Lester M. Crawford, D.V.M., Ph.D., FDA deputy commissioner, has been named the new commissioner of the FDA, which is located in Rockville, Md. Dr. Crawford has extensive experience in FDA matters. His previous government experience includes serving as head of FDA’s Center for Veterinary Medicine and, from 1987 to 1991, as administrator of the Department of Agriculture’s Food Safety and Inspection Service. From 1993 to 1997, Dr. Crawford was the executive director of the Association of American Veterinary Medical Colleges. Dr. Crawford has a doctorate in veterinary medicine from Auburn University and he also earned a Ph.D. degree in pharmacology from the University of Georgia. He has an honorary doctorate from Budapest University. He has written more than 100 scientific papers and has co-authored 6 books. He is a fellow of the Royal Society of Medicine (U.K.), and also is a fellow of the International Society of Food Science and Technology. In addition, the FDA is operating on a three deputy commissioner system on an acting basis until further notice. Dr. Janet Woodcock is deputy commissioner for operations, Dr. Murray Lumpkin will be deputy commissioner for special programs, and Amit Sachdev will become deputy commissioner for policy. Mary-Lacey Reuther has been appointed director of departmental and interdepartmental relations, coordinating FDA inter- actions with the Department of Health and Human Services and other cabinet departments. Dr. Scott Gottlieb has been appointed director of medical policy development, coordinating office of commissioner liaison with the Centers for Biologics Evaluation and Research, Medical Devices and Radiological Health and Drug Evaluation and Research. Susan Bond has been appointed director of scientific policy development, coordinating Office of Commissioner liaison with the Center for Food Safety and Applied Nutrition, the National Center for Toxicological Research, and the Center for Veterinary Medicine. Lester M. Crawford (above top) has been named commissioner of the FDA to replace Mark McClellan, who is leaving the agency to become head of the Centers for Medicare and Medicaid Services. Lester M. Crawford (above top) has been named commissioner of the FDA to replace Mark McClellan, who is leaving the agency to become head of the Centers for Medicare and Medicaid Services. Lester M. Crawford (above top) has been named commissioner of the FDA to replace Mark McClellan, who is leaving the agency to become head of the Centers for Medicare and Medicaid Services.

Posted in:

Post a Comment

You must be logged in to post a Comment.